Best Peptides For Libido
Best Peptides for Libido: Ranked, Cited Guide
The short answer
The best peptides for libido, by weight of human evidence, are PT-141 (bremelanotide), an MC4R agonist, and kisspeptin-54, a reproductive-axis signaling peptide (Kingsberg et al., 2019; Mills et al., 2023).
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What are the best peptides for libido?
The best peptides for libido, judged by controlled human data, are PT-141 (bremelanotide) and kisspeptin-54, and only PT-141 has a completed phase 3 program and approval.
"Best" here means best-evidenced, not most-hyped. Most peptides marketed for sexual function have little or no controlled human data. Two stand apart because they were tested in randomized trials with sexual-function endpoints. PT-141 acts on melanocortin receptors in the brain (Kingsberg et al., 2019). Kisspeptin-54 acts higher up the reproductive-signaling axis (Dhillo et al., 2005). They work by different mechanisms, were studied in different populations, and carry different evidence weight.
How do PT-141 and kisspeptin-54 compare?
PT-141 is an approved MC4R agonist with the largest trial base, while kisspeptin-54 is earlier-stage but shows measurable effects on arousal signaling in both sexes.
| Compound | Mechanism | Population studied | Regulatory status | Key reported side effect |
|---|---|---|---|---|
| PT-141 (bremelanotide) | Melanocortin-4 receptor (MC4R) agonist acting centrally | Premenopausal women with generalized HSDD | FDA-approved as Vyleesi for premenopausal HSDD (Kingsberg et al., 2019) | Nausea in roughly 40 percent at 1.75 mg (Kingsberg et al., 2019) |
| Kisspeptin-54 | Reproductive-axis signaling peptide upstream of GnRH | Men with low sexual desire; healthy adults | No approval for sexual indications; RCT-stage (Mills et al., 2023; Comninos et al., 2017) | Well tolerated in reported crossover trials (Mills et al., 2023) |
Why is PT-141 ranked first?
PT-141 ranks first because it is the only libido-focused peptide with a completed phase 3 program and regulatory approval.
PT-141 is a melanocortin-4 receptor agonist that acts in the central nervous system rather than on blood flow, which sets it apart from erectile-focused drugs (Kingsberg et al., 2019). The RECONNECT phase 3 program, reported as two randomized, double-blind, placebo-controlled trials (Study 301 and Study 302), supported approval as Vyleesi for premenopausal women with generalized acquired HSDD (Kingsberg et al., 2019). Earlier controlled work in men also reported effects on erectile response in a double-blind, placebo-controlled study of intranasal PT-141 (Diamond et al., 2004). Across the phase 3 dataset, nausea was the most commonly reported side effect, occurring in about 40 percent of participants at the 1.75 mg dose, alongside flushing and headache (Kingsberg et al., 2019). The approval and the size of the trial base are why it leads this list.
Why is kisspeptin-54 ranked second?
Kisspeptin-54 ranks second because it has real randomized human data across both sexes, but no approval for sexual indications yet.
Kisspeptin is a signaling peptide that sits upstream in the reproductive axis (Dhillo et al., 2005). In a placebo-controlled crossover randomized clinical trial in men with HSDD, kisspeptin administration increased penile tumescence in response to sexual stimuli by up to 56 percent more than placebo, reported as a secondary measure, with associated changes in sexual brain processing (Mills et al., 2023). Earlier controlled work found that kisspeptin modulated activity in brain regions tied to sexual and emotional processing in healthy adults (Comninos et al., 2017). These are small, early studies, and the compound is not approved for sexual use, which places it behind PT-141 in evidence weight while still ahead of the many peptides with no controlled sexual-function data at all.
What dosing has research reported?
Published trials report specific dose ranges, but these are trial descriptions, not instructions, and a personal dose is a clinician's decision.
The system rules here do not permit dosing guidance. What can be said is that PT-141's approved formulation and the kisspeptin trials used defined, controlled amounts under medical supervision (Kingsberg et al., 2019; Mills et al., 2023). If you are weighing any of this, the correct next step is a conversation with a qualified clinician who can review your history, not a dose copied from a study abstract.
Who might each compound suit in the research context?
PT-141 was studied in premenopausal women with HSDD, while kisspeptin trials enrolled men with low desire and healthy adults, so the research populations differ sharply.
The RECONNECT program studied premenopausal women with generalized acquired HSDD (Kingsberg et al., 2019). The kisspeptin work studied men with HSDD and, separately, healthy adults in brain-imaging protocols (Mills et al., 2023; Comninos et al., 2017). Because the studied populations, endpoints, and approval status all differ, the two are not interchangeable, and neither substitutes for a clinical evaluation.
Keep reading
Related research and verification
Best Peptides For Libido: FAQ
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
References
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology. 2019;134(5):899 to 908. (PMID 31599840, PMC6819021). The RECONNECT phase 3 program supporting approval of PT-141 (bremelanotide) as an MC4R agonist for premenopausal HSDD, with nausea the most common side effect at the 1.75 mg dose.
- Mills EG, Ertl N, Wall MB, et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network Open. 2023;6(2):e2254313. doi:10.1001/jamanetworkopen.2022.54313. Placebo-controlled crossover trial reporting kisspeptin raised penile tumescence by up to 56 percent more than placebo in men with HSDD.
- Comninos AN, Wall MB, Demetriou L, et al. Kisspeptin modulates sexual and emotional brain processing in humans. Journal of Clinical Investigation. 2017;127(2):709 to 719. doi:10.1172/JCI89519 (PMID 28112678). Randomized crossover study reporting kisspeptin modulated brain activity tied to sexual and emotional processing.
- Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary-gonadal axis in human males. Journal of Clinical Endocrinology and Metabolism. 2005;90(12):6609 to 6615. doi:10.1210/jc.2005-1468 (PMID 16174713). Establishes kisspeptin-54 as a reproductive-axis signaling peptide in men.
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004;16(1):51 to 59. (PMID 14963471). Earlier controlled study reporting effects of intranasal PT-141 on erectile response in men.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.